BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Pfizer Limited submitted on 30 August 2005 an application for Marketing Authorisation 
to the European Medicines Agency (EMEA) through the centralised procedure for SUTENT, which 
was designated as an orphan medicinal product EU/3/05/267 and EU/3/05/268 on 10 March 2005.  
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur:  
Pasqualino Rossi 
Co-Rapporteur:  
Jens Ersbøll 
Orphan Drugs: 
SUTENTwas designated as an orphan medicinal product in the following indications:  treatment of 
malignant gastrointestinal stromal tumour (GIST) and renal cell carcinoma. 
Scientific Advice: 
The applicant did not seek scientific advice the CHMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 28 September 2005.  
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  12 
December  2005.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 14 December 2005.  
The  CHMP  adopted  a  report  on  similarity  of  SUTENT  with  authorised  orphan  medicinal 
products for the same therapeutic indication on 14 December 2005.  
During  the  meeting  on  23-26  January  2006,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant, and questions for the CHMP Scientific Advisory Group 
(SAG)  for  Oncology.  The  final  consolidated  List  of  Questions  was  sent  to  the  applicant  on  3 
February 2006.  
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  and 
questions for the CHMP Scientific Advisory Group (SAG) for Oncology on 21 February 2006 
and  2  March  2006.    The  applicant  submitted  additional  responses  to  the  CHMP  consolidated 
List of Questions on 5 April 2006. 
During  a  meeting  of  a  SAG-Oncology  on  9  March  2006,  experts  were  convened  to  address 
questions raised by the CHMP. The Applicant presented the Applicant’s views on the questions 
related to SUTENT. Answers and comments were given by the group. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 27 March 2006. The Rapporteurs circulated an 
addendum to the Joint Assessment Report on the applicant’s responses to the List of Questions 
to all CHMP members on 10 April 2006. 
During the meeting on 24-27 April 2006, the CHMP, in the light of the overall data submitted 
and the scientific discussion within the Committee, issued a positive opinion for granting a 
conditional Marketing Authorisation to SUTENTon 27 April 2006. The applicant provided the 
letter of undertaking on the specific obligation and follow-up measures to be fulfilled post-
authorisation on 26 April 2006. 
The CHMP opinions were forward, in all official languages of the European Union, to the 
European Commission, which adopted the corresponding decision on 19 July 2006. 
1/1 
EMEA 2006 
 
 
 
 
 
 
 
 
 
 
 
